Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relistor in acute pancreatitis
NCT04743570Phase 3Completed
- Start
- May 2021
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of methylnaltrexone in acute pancreatitis (AP). Primary endpoint: Pancreatitis activity scoring system at 48 hours. Started May 2021; status: completed.
02
Drugs
methylnaltrexone
03
Conditions
acute pancreatitis (AP)
Beyond the preview
Go deeper on NCT04743570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04743570.